



## News Release

### **Suven Awarded Phase III Clinical study for Chronic Low Back pain.**

*Retained to provide comprehensive clinical trial program under Phase III for a Global Life Science company*

**HYDERABAD, INDIA (October 11, 2005)** – Suven Life Sciences Limited (Suven) today announced that it is starting 12 months multi center Phase III clinical study for Chronic Low Back pain in India. The study is part of global study for a US based Biopharmaceutical Company focused on discovery, in-licensing, development and commercialization of novel drug candidates for central nervous system (CNS) cardiovascular disorders and pain management. One of the products under development for chronic low back pain has reached the stage of Phase III clinical trial and about 1550 patients are being enrolled globally for pain management. Part of the study being conducted in India with a minimum enrolment of 300 patients and the contract was awarded to Suven Life Sciences. The contract value is around \$ 2 million spread over a period of 18 months. Suven is also in advanced discussions to carry out 2 more Phase III studies in CNS for the same sponsor.

Suven Life Sciences, a Hyderabad based life sciences company, pioneer in Contract Research And Manufacturing Services ( CRAMS ) since 1995 in its endeavor to become collaborative research partner (CRP) for global life science companies has embarked on new business model “Drug Discovery and Development Support Services” ( DDDSS ) with the onset of Intellectual Property Regime in India since January 2005. This model has resulted in Suven getting an award “ Partner of Choice in Drug Discovery for CNS” by Frost & Sullivan for 2005. Under DDDSS business model Suven provides services from preclinical through clinical development and clinical data management in addition to CRAMS for global pharmaceutical and life science companies.

A focused provider of DDDSS for development of New Chemical Entities to life sciences companies, Suven's commitment to protection of intellectual property, maximization of return on R&D investments for collaborative research partners, ability to offer full spectrum of services from discovery to market launch and provide technologies and expertise in different therapeutic areas. Suven has R&D strength of more than 170 professionals with the state of the art infrastructure for Drug Discovery and development activities with 30 clinical research professionals and the front end project management services from New Jersey , USA . For more information on Suven, please visit our Web site at <http://www.suven.com> .

**Risk Statement:**

*Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;*